


PHARMACEUTICAL 2020

BeiGene Ltd. Rank 223 of 362









PHARMACEUTICAL 2020



BeiGene Ltd. Rank 223 of 362

The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 51% points. The greatest weakness of BeiGene Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 121% points.

The company's Economic Capital Ratio, given in the ranking table, is -249%, being 54% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,172,696
Cost of Goods Sold	71,190
Intangible Assets	5,846
Liabilities, Current	310,312
Liabilities, Non-Current	323,622
Other Assets	191,345
Other Compr. Net Income	-7,577
Other Expenses	8,318
Other Liabilities	0
Other Net Income	16,305
Property and Equipment	242,402
Research and Development	927,338
Revenues	428,212
Selling, General and Administrative Expense	388,249

Output Variable	Value in 1000 USD
Assets	1,612,289
Liabilities	633,934
Expenses	1,395,095
Stockholders Equity	978,355
Net Income	-950,578
Comprehensive Net Income	-954,366
Economic Capital Ratio	-249%

